Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Judah Frommer lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $123.00 (from $127.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
